Taysha Gene Therapies (TSHA) Interest & Investment Income (2023 - 2026)

Taysha Gene Therapies (TSHA) has 4 years of Interest & Investment Income data on file, last reported at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income rose 95.02% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (up 59.5% YoY), and the FY2025 full-year result was $9.2 million, up 32.91% from the prior year.
• Interest & Investment Income eased to $2.6 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.2 million in Q3 2025 to a low of $1.1 million in Q3 2023.
• A 4-year average of $2.0 million and a median of $1.9 million in 2025 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income decreased 21.68% in 2025 and surged 95.02% in 2026, its largest moves.
• Tracing TSHA's Interest & Investment Income over 4 years: stood at $1.9 million in 2023, then fell by 11.5% to $1.7 million in 2024, then surged by 68.82% to $2.9 million in 2025, then declined by 9.9% to $2.6 million in 2026.
• Business Quant data shows TSHA's Interest & Investment Income at $2.6 million in Q1 2026, $2.9 million in Q4 2025, and $3.2 million in Q3 2025.